189 related articles for article (PubMed ID: 22086665)
1. Medication-assisted treatment research with criminal justice populations: challenges of implementation.
Gordon MS; Kinlock TW; Miller PM
Behav Sci Law; 2011; 29(6):829-45. PubMed ID: 22086665
[TBL] [Abstract][Full Text] [Related]
2. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Friedmann PD; Hoskinson R; Gordon M; Schwartz R; Kinlock T; Knight K; Flynn PM; Welsh WN; Stein LA; Sacks S; O'Connell DJ; Knudsen HK; Shafer MS; Hall E; Frisman LK;
Subst Abus; 2012; 33(1):9-18. PubMed ID: 22263709
[TBL] [Abstract][Full Text] [Related]
3. Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Colker AC
Issue Brief Health Policy Track Serv; 2002 Dec; ():1-6. PubMed ID: 12875273
[No Abstract] [Full Text] [Related]
4. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
[TBL] [Abstract][Full Text] [Related]
5. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
[TBL] [Abstract][Full Text] [Related]
6. Regarding naltrexone for probationers and parolees.
Stancliff S
J Subst Abuse Treat; 2007 Mar; 32(2):217-8; author reply 218-9. PubMed ID: 17306730
[No Abstract] [Full Text] [Related]
7. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
8. Research on naltrexone in the criminal justice system.
Patapis NS; Nordstrom BR
J Subst Abuse Treat; 2006 Sep; 31(2):113-5. PubMed ID: 16919735
[TBL] [Abstract][Full Text] [Related]
9. Clinical treatment of opioid addiction and dependence.
Ling W; Rawson RA; Compton M
Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
[No Abstract] [Full Text] [Related]
10. Pharmacotherapy for opioid addiction in community corrections.
Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
[TBL] [Abstract][Full Text] [Related]
11. Update on pharmacotherapy for treatment of opioid use disorder.
Ayanga D; Shorter D; Kosten TR
Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
[TBL] [Abstract][Full Text] [Related]
12. The diverse clinical uses of opioid receptor drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
[TBL] [Abstract][Full Text] [Related]
13. Use of naltrexone in treating opioid use disorder in pregnancy.
Towers CV; Katz E; Weitz B; Visconti K
Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
[TBL] [Abstract][Full Text] [Related]
14. Criminal justice continuum for opioid users at risk of overdose.
Brinkley-Rubinstein L; Zaller N; Martino S; Cloud DH; McCauley E; Heise A; Seal D
Addict Behav; 2018 Nov; 86():104-110. PubMed ID: 29544869
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of addictions.
Kreek MJ; LaForge KS; Butelman E
Nat Rev Drug Discov; 2002 Sep; 1(9):710-26. PubMed ID: 12209151
[TBL] [Abstract][Full Text] [Related]
16. Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Park TW; Friedmann PD
R I Med J (2013); 2014 Oct; 97(10):20-4. PubMed ID: 25271655
[TBL] [Abstract][Full Text] [Related]
17. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
Holtzman SG
J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
[TBL] [Abstract][Full Text] [Related]
18. Long-term course of opioid addiction.
Hser YI; Evans E; Grella C; Ling W; Anglin D
Harv Rev Psychiatry; 2015; 23(2):76-89. PubMed ID: 25747921
[TBL] [Abstract][Full Text] [Related]
19. Narcotic antagonist treatment of the criminal justice patient-institutional vs outpatient-including a 24 hour detox naltrexone induction regimen with oral medication.
Brahen L; Wiechert V; Capone T
NIDA Res Monogr; 1976 Sep; (9):93-8. PubMed ID: 794727
[No Abstract] [Full Text] [Related]
20. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
